FDA review docs spark Revolution sell-off; Zealand diabetes data underwhelm analysts
The new disclosure suggested Rasonque might not be as broadly effective as previously thought. Elsewhere, Ultragenyx got a much-needed cash infusion and TCGX started a China-focused fund.